293 related articles for article (PubMed ID: 26643352)
1. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
2. Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
Lanoix JP; Ioerger T; Ormond A; Kaya F; Sacchettini J; Dartois V; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):735-43. PubMed ID: 26574016
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Lanoix JP; Lenaerts AJ; Nuermberger EL
Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
6. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
7. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
[TBL] [Abstract][Full Text] [Related]
9. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.
Williams KN; Brickner SJ; Stover CK; Zhu T; Ogden A; Tasneen R; Tyagi S; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2009 Aug; 180(4):371-6. PubMed ID: 19520903
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.
Li SY; Irwin SM; Converse PJ; Mdluli KE; Lenaerts AJ; Nuermberger EL
Antimicrob Agents Chemother; 2015 Jul; 59(7):4026-30. PubMed ID: 25918146
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in
Irwin SM; Prideaux B; Lyon ER; Zimmerman MD; Brooks EJ; Schrupp CA; Chen C; Reichlen MJ; Asay BC; Voskuil MI; Nuermberger EL; Andries K; Lyons MA; Dartois V; Lenaerts AJ
ACS Infect Dis; 2016 Apr; 2(4):251-267. PubMed ID: 27227164
[TBL] [Abstract][Full Text] [Related]
12. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
[TBL] [Abstract][Full Text] [Related]
13. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Harper J; Skerry C; Davis SL; Tasneen R; Weir M; Kramnik I; Bishai WR; Pomper MG; Nuermberger EL; Jain SK
J Infect Dis; 2012 Feb; 205(4):595-602. PubMed ID: 22198962
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
[TBL] [Abstract][Full Text] [Related]
15. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
[TBL] [Abstract][Full Text] [Related]
17. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Mitchison DA; Nunn AJ
Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
[TBL] [Abstract][Full Text] [Related]
18. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
20. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
